The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy

Launched by HISTOSONICS, INC. · Feb 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called the HistoSonics Edison™ System, which uses a technique called histotripsy to destroy pancreatic adenocarcinoma, a type of pancreatic cancer that cannot be surgically removed. The goal of the trial is to evaluate how safe this treatment is for patients who have this type of cancer. The trial is currently looking for participants who are at least 18 years old and have been diagnosed with advanced pancreatic adenocarcinoma that cannot be treated with surgery. Eligible participants should also have received chemotherapy for at least 16 weeks or cannot tolerate chemotherapy due to side effects.

If you decide to participate, you’ll receive treatment using the HistoSonics Edison System, which is designed to target and destroy the tumor in your pancreas. The trial is open to individuals of all genders, and only one tumor will be treated during the procedure. It's important to note that participants will need to meet specific health criteria to ensure their safety during the trial. If you have any questions about your eligibility or the trial process, the research team is there to help you understand what to expect.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject is ≥18 years of age.
• • 2. Subject has signed the Ethics Committee (EC) approved trial Informed Consent Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments.
• • 3. Subject is diagnosed with unresectable pancreatic adenocarcinoma, locally advanced (Stage 3) or oligometastatic disease (Stage 4) confirmed via CT or MR imaging ≤30 days prior to the index procedure date.
• • NOTE: If Stage 4 disease, there must be ≤5 metastatic tumors and the tumors are located only in the liver and/or lung.
• • 4. Subject is not a surgical candidate and has received chemotherapy ≥8 weeks.
• • 5. Subject can tolerate general anesthesia.
• • 6. Subject has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-1 at baseline.
• 7. Subject meets the following criteria ≤14 days prior to the planned index procedure date:
• • Hemoglobin ≥ 9 g/dL,
• • Neutrophil count \>1.0 x 10\^9/L,
• • Platelet \>50 x 10\^9/L,
• • Total bilirubin ≤2.5x Institutional Upper Limit of Normal (IULN),
• • Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.5x IULN,
• • International Normalized Ratio (INR) value \<1.5,
• • Serum creatinine \<2.0mg/dL or an estimated glomerular filtration rate (eGFR) ≥45mL/min.
• • 8. The targeted pancreatic tumor is ≥2 cm in longest diameter.
• • 9. The planned histotripsy treatment volume is ≥1.0 cm from any portion of the duodenum, small intestine, stomach, or colon as visualized on ultrasound, and CT, or MR imaging.
• • 10. Subject has an adequate acoustic window to visualize targeted tumor using the HistoSonics Edison System.
• • 11. Subject will undergo histotripsy treatment of only one (1) tumor during the index procedure, regardless of how many tumors are present in the pancreas.
• Exclusion Criteria:
• • 1. Subject is pregnant or planning to become pregnant or nursing (lactating) during the trial period.
• • 2. Subject has had prior pancreatic, bilioenteric, or gastric surgery.
• • 3. Subject is being actively treated in another pharmaceutical or device trial that has not completed its primary endpoint prior to the index procedure or may interfere with the primary outcome measure of this trial.
• • 4. Subject has an uncorrectable coagulopathy.
• • 5. Subject has a life expectancy of less than six (6) months.
• • 6. Subject has a biliary or pancreatic stent and/or percutaneous biliary tube that encompasses the planned histotripsy treatment volume.
• • 7. Subject has metastases to organs other than the liver and/or lung (e.g., bone, brain, peritoneum).
• • 8. Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.
• • 9. Subject has an active duodenal or gastric ulcer requiring medical management.
• • 10. Subject is undergoing active chemotherapy for any cancer ≤14 days prior to planned index procedure date.
• • 11. Subject is undergoing active immunotherapy ≤30 days prior to planned index procedure date.
• • 12. Subject's targeted tumor has had prior locoregional therapy (e.g., ablation, embolization, or radiation).
• • 13. Subject has a planned cancer treatment (e.g., pancreatic surgery, chemotherapy, immunotherapy, etc.) prior to completion of the 30-day follow-up visit.
• • 14. Subject has not recovered (CTCAE grade 2 or better) from chemotherapy or immunotherapy related toxicities (exclusive of alopecia, neuropathy, and exocrine insufficiency).
• • 15. In the investigator's opinion, histotripsy is not a treatment option for the subject.
• • 16. Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.
• • 17. Subject's tumor is not treatable by the System's working ranges (refer to User Guide).